Biointron
百英生物
Biointron (百英生物) is an antibody-discovery CRO founded in 2012, operating R&D and production bases in Shanghai Zhoupu and Jiangsu Taizhou with a US commercial and logistics office . The company runs a high-throughput recombinant protein preparation platform that spans the full antibody-discovery pipeline — from target-protein development and single-B-cell screening to antibody humanization, affinity maturation, nanobody development, and stable cell-line development — and has served over a thousand downstream life-science clients globally . In August 2022 it closed a nearly RMB 500 million Series B round led by Cornerstone Capital, Jifeng Capital, Gaorong Ventures, Tianhui Capital, and Haitong Venture Capital, with follow-on participation from existing shareholders Furong Investment and Chengshu Investment; proceeds were earmarked for expanding CRO service capacity, building smart-manufacturing R&D service lines, and strengthening overseas channels . Gaorong Ventures listed Biointron among its portfolio companies as of May 2025 .
AI-generated — may contain errors, please verify.
Coverage
Congratulations to Mirxes on its successful listing on the Hong Kong Stock Exchange's Main Board — Gaorong Ventures was its earliest institutional investor.
A leading provider of molecular cancer screening products and services.
Robotics, SaaS, and innovative drug sectors close new funding rounds; chips and medical devices unveil major new products | Rongbao · August
Differentiated innovation and global opportunities.
Antibody discovery CRO **Baiying Biotech** closes nearly RMB 500 million Series B round
Specializing in antibody discovery CRO services to accelerate antibody drug development.
